Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up – Should You Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $38.24, but opened at $41.62. Celldex Therapeutics shares last traded at $38.3170, with a volume of 28,369 shares.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CLDX. Wells Fargo & Company lifted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a report on Monday, June 15th. Finally, Guggenheim upped their target price on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.42.

Celldex Therapeutics Price Performance

The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of -8.73 and a beta of 0.84. The firm’s fifty day moving average price is $39.13 and its 200-day moving average price is $34.75.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.73 million. On average, research analysts predict that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 11.5% during the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock worth $355,120,000 after purchasing an additional 983,195 shares during the period. Commodore Capital LP lifted its stake in Celldex Therapeutics by 5.1% in the first quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after buying an additional 131,616 shares during the period. Eversept Partners LP lifted its stake in Celldex Therapeutics by 24.6% in the first quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock valued at $56,716,000 after buying an additional 353,291 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Celldex Therapeutics by 62.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock worth $33,596,000 after buying an additional 407,818 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Celldex Therapeutics by 1.1% during the 4th quarter. Fisher Asset Management LLC now owns 937,158 shares of the biopharmaceutical company’s stock worth $25,453,000 after buying an additional 10,001 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.